Vaginal tumours in childhood: a descriptive analysis from a large paediatric medical centre

Meng, Zhaoyi; Lin, Defu; Liu, Chao; Wang, Guan-An; Sun, Ning

doi:10.1007/s00383-022-05085-3

Cited by 4 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rhabdomyosarcoma (RMS) is considered the most common pathological type of vaginal tumor in prepubertal females, followed by YST (18). However, Meng et al (19) found that YST may be the most common pathological type of vaginal tumor in Chinese children, followed by RMS. Vaginal YST should be considered for a young girl with vaginal bleeding.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, it is not clear whether the best time to operate is before or after chemotherapy. After reviewing treatment options published over the past 20 years, it was found that conservative treatment is showing a growing trend (2,11,18,19,36,37). A number of studies tended to adopt a biopsy combined with chemotherapy or chemotherapy combined with conservative surgery (38,39).…”

Section: Discussionmentioning

confidence: 99%

“…For infants and young children with vaginal YSTs, chemotherapy alone can also eliminate tumor tissue and restore serum AFP to a normal level according to some reports (9,18,19,36,41,42), which may avoid damaging vaginal or pelvic structures. Neels et al (43) suggested that vaginal YST with distant metastases and good response to chemotherapy could be cured with intensive chemotherapy without surgery after their study.…”

Section: Discussionmentioning

confidence: 99%

“…However, it is hard to fully assess the long-term consequences of these toxic effects, as such a case is still in the minority. The PEB chemotherapy regimen is currently considered to be the most effective regimen with minimal side effects (19,44). Yuan et al (15) suggested that PEB chemotherapy should be adopted for patients who experienced early stage disease and received non-surgical treatment.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Vaginal yolk sac tumors in infants and children: A case report and literature review

2023

Oncol Lett

View full text Add to dashboard Cite

A vaginal yolk sac tumor (YST) is a rare malignant germ cell tumor for infants and children, and it has been >50 years since the first case was reported. The treatment strategy has changed markedly in the past 50 years, from radical surgical treatment to conservative surgery combined with chemotherapy, and then to combined chemotherapy alone. The present study reports the case of a primary vaginal YST in a 13-month-old girl that was successfully treated by tumor resection combined with chemotherapy. The clinical symptoms, imaging features and treatment characteristics are described in detail, as well as the postoperative treatment. There was no local recurrence or metastasis for the 2 years of follow-up to date. A literature review was also conducted to investigate the clinicopathological features, treatment and prognosis of this tumor. Overall, surgery combined with bleomycin, etoposide and carboplatin combination chemotherapy can be an effective option for vaginal YST.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vaginal yolk sac tumors in infants and children: A case report and literature review

2023

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Some studies recommend partial vaginal resection for residual lesions. Meng et al claimed that surgical resection could not only remove residual lesions but also confirm the presence of active tumor cells through pathology so as to provide a basis for subsequent treatment [17]. Tang et al considered that chemotherapy alone was more suitable for simple yolk sac tumors, but tumors with other mixed germ cell components should be treated with chemotherapy combined with local surgery [18].…”

Section: Discussionmentioning

confidence: 99%

Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center

et al. 2022

View full text Add to dashboard Cite

Background The objective of the study was to analyze the clinical features, treatment, and outcomes of primary vaginal endodermal sinus tumor (EST) in infants and children treated in a tertiary center. Methods Clinical data of patients with pathologically confirmed primary vaginal EST in our hospital from January 1997 to December 2017 were retrospectively reviewed and analyzed. Results A total of 21 patients were included in this study. The median age at diagnosis was 11 months (range, 4–44 months). The most common manifestations were abnormal vaginal bleeding, and a polypoid mass protruding from the vagina. Chemotherapy based on PEB (cisplatin, etoposide, bleomycin) regimen was given, and serum alpha-fetoprotein (AFP) levels dropped to normal levels after 2 to 4 cycles of chemotherapy (median, 2 cycles). After 3 to 13 cycles of chemotherapy, with a median of 5 cycles, 20 patients achieved complete remission (95.2%). The median follow-up time was 80 months (range, 4-281months). At the time of the last follow-up, 19 cases were alive without disease, and the survival rate was 90.5%. Conclusion Vaginal EST is a very rare malignant germ cell tumor and is sensitive to chemotherapy. Conservative surgery combined with PEB chemotherapy is an effective way of treatment. Serum AFP and imaging examinations can monitor the treatment response and recurrence.

show abstract

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Vaginal tumours in childhood: a descriptive analysis from a large paediatric medical centre

Cited by 4 publications

References 28 publications

Vaginal yolk sac tumors in infants and children: A case report and literature review

Vaginal yolk sac tumors in infants and children: A case report and literature review

Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center

Antineoplastics

Contact Info

Product

Resources

About